These findings highlight miR‐137 as a crucial suppressor of CC progression through its negative regulation of Notch1 and the PI3K/AKT/mTOR pathway, revealing a potential therapeutic axis for targeted intervention. Here, MTOR is linked to cholangiocarcinoma.